Innoviva, Inc. (FRA:HVE)

Market Cap	1.26B +14.2%
Revenue (ttm)	331.14M +10.1%
Net Income	108.54M +97.2%
EPS	1.30 +54.0%
Shares Out	n/a
PE Ratio	11.60
Forward PE	8.72
Dividend	n/a
Ex-Dividend Date	n/a

Volume	n/a
Average Volume	n/a
Open	16.20
Previous Close	16.30
Day's Range	16.20 - 16.20
52-Week Range	14.20 - 19.20
Beta	n/a
RSI	52.83
Earnings Date	Feb 26, 2026

About Innoviva

Innoviva, Inc. engages in the development and commercialization of pharmaceutical products in the United States and internationally. The company’s products include RELVAR/BREO ELLIPTA, a once-daily combination medicine consisting of a LABA, vilanterol (VI), an inhaled corticosteroid (ICS), and fluticasone furoate; ANORO ELLIPTA, a once-daily medicine combining a long-acting muscarinic antagonist (LAMA) and umeclidinium bromide (UMEC) with a LABA, VI; GIAPREZA (angiotensin II), a vasoconstrictor to increase blood pressure in adults with septic o...

• Industry: Biological Products, Except Diagnostic Substances
• Founded: 1996
• Employees: 127
• Stock Exchange: Frankfurt Stock Exchange
• Ticker Symbol: HVE

Financial Performance

In 2024, Innoviva's revenue was $358.71 million, an increase of 15.54% compared to the previous year's $310.46 million. Earnings were $23.39 million, a decrease of -86.98%.

Financial numbers in USD